2024

Awarded the title of 'National High-tech Enterprise' for 17 consecutive years Awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for 8 consecutive years Submitted registration applications for 10 formulation products in China, obtaining over 80 various registration approvals Obtained registration numbers for 10 active pharmaceutical ingredients from FDA, CDE, Taiwan Ministry of Health and Welfare, and other institutions Submitted 12 new patent applications, with a total of over 60 invention patents Achieved a cumulative factory technology transfer of over 130 items to client companies

2023

Awarded the title of 'National High-tech Enterprise' for 16 consecutive years Awarded the title of 'Top 20 Pharmaceutical R&D Companies in China' for 7 consecutive years Has obtained more than 70 clinical, production licenses, and new drug certificates approved by the National Medical Products Administration of China Has submitted more than 10 international registration applications to the FDA, EU, etc. Cumulatively achieved over a hundred technology transfers to client companies Completed multiple technology achievements transformation and industrialized production of over 30 series products

2022

More than 20 new invention patent applications Two raw material drug varieties registered with CDE transferred to A Five formulation varieties obtained production licenses Shanghai branch established to strengthen business expansion and layout

2021

Obtain the first CEP certificateObtain CNAS certification certificate First submission of MAH certification and obtain B certificate Two raw material drug varieties CDE transfer to A

2020

The R&D office building of Jinghai Industrial Park is officially in use. Establish a strategic partnership with Zezheng Pharmaceutical.

2019

The subsidiary Haimei Ocean was established, and international business operates independently. Submitted registration applications to the EU and FDA Ranked among the top 20 pharmaceutical R&D companies in China for consecutive years Pilot unit for integration of informatization and industrialization Won the T100 New Technology and New Product Innovation Action Enterprise Award

2018

Establish a strategic partnership with PPC Jiaseng Consecutively ranked among the top 20 pharmaceutical R&D companies in China

2017

Establish a strategic partnership with Boteng Pharmaceutical Awarded the title of one of the top 20 pharmaceutical R&D companies in China

2016

The subsidiary Haimeiyuan was established, and the CRO business operates independently.

2015

The subsidiary Haimeitong was established, and the raw materials and intermediates business operates independently. Establish an employee stock ownership platform and complete the shareholding system transformation.

2013

Obtain the first patent certificate

2012

Obtained the first new drug certificate Obtained the Beijing municipal enterprise technology research and development institution certificate First accepted foreign customer audit

2011

Investing in Shandong Kongfu Pharmaceutical

2008

Establish a strategic partnership with Beihua Hengye

2007

Awarded the title of National High-tech Enterprise

2006

Establish a new drug research and development center

2005

Established Haibu Pharmaceutical